C. Fitzsimon

Cost of Chickenpox in Canada: Part I. Cost of Uncomplicated Cases

S. Halperin, P. Déry, L. Ford-Jones, 1999, Pediatrics.

Drug utilization review of celecoxib in Ontario.

J. LeLorier, F. Lavoie, C. Fitzsimon, 2003, Rheumatology.

An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada

J. Chancellor, T. Burke, F. Lavoie, 2012, PharmacoEconomics.

Cost of Chickenpox in Canada: Part II. Cost of Complicated Cases and Total Economic Impact

L. Ford-Jones, B. Law, J. McCormick, 1999, Pediatrics.

Economic benefits of a routine second dose of combined measles, mumps and rubella vaccine in Canada.

C. Levinton, R. Tretiak, C. Leclerc, 1997, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.

R. Tretiak, C. Leclerc, C. Fitzsimon, 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.

J. Pellissier, C. Fitzsimon, W. Cassidy, 2001, Pediatrics.